Agnes Dosa

Agnes Dosa

Auto-generated profile, based on publicly available information

Agnes Dosa

Semmelweis University Medical School, Budapest, Hungary

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
EMEva Mezey
Eva Mezey
ISIldikó Szalayova
Ildikó Szalayova
CHChristopher T. Hogden
Christopher T. Hogden
ABAlexandra Brady
Alexandra Brady
ÁDÁgnes Dósa
Ágnes Dósa
MPMiklós Palkovits
Miklós Palkovits
Significance: The connection between brain and peripheral lymphatics has been studied for 250 y, mainly in animals. Specific markers for lymphatic endothelial cells (LECs) were discovered about a decade ago. We stained postmortem human brains with LYVE1 and PDPN to identify LECs. Marker-positive cells were found in membranes covering the brain, walls of vessels, and perivascular spaces, and among nerve fibers. These spaces also seem to contain T cells and are connected to peripheral lymphatics through passageways in the nasal cavity, optic nerve, and base of the skull. Our findings show a path that brain waste products take when they leave the central nervous system, paths that may be bidirectional.

29 July 2021 in Clinical and Experimental Nephrology
Verified
Journal Article
Open access
PDF file
GCGabor Cserep
Gabor Cserep
DMDavid Morrow
David Morrow
KLKaren Latchford
Karen Latchford
RJRachael Jesset
Rachael Jesset
ADAgnes Dosa
Agnes Dosa
DKDimitrios Kirmizis
Dimitrios Kirmizis
Introduction In this single-centre retrospective observational study, the 8-week safety and the efficiency of a single dose of BNT162b2 vaccine was studied in 83 HD patients. Methods All clinically stable adult ESRD patients on chronic HD for at least 4 weeks were screened for participation in the study. Exclusion criteria for enrollment in the study included a medical history of COVID-19 infection within the last 12 weeks or delivery of both vaccine doses less than 8 weeks apart from each other. The same patients during the 8-week period that preceded the vaccination served as controls of themselves. The vaccine was administered intramuscularly in the deltoid muscle, on a dialysis day, at least 30 min either pre- or post-dialysis. The primary end-point of the study was severe COVID-19 infection, and/or death due to COVID-19 pneumonitis. Furthermore, all vaccinated patients were scrutinized for any local or systemic reactions within the first 7 days post-vaccination. Results Amongst 113 adult HD patients in our Unit, in total 83 patients had the first 30 μg dose of the BNT162b2 vaccine and were considered eligible to be included in the study. The 8-week survival rate was 91% for the controls and 100% for the vaccine group. No life-threatening allergic reaction or other side-effect was observed post-vaccination. Conclusion The BNT162b2 vaccine can be safely used in HD patients and seems to offer significant protection against the infection even after the first vaccine dose.